Quantum BioPharma Announces New Marketing Partnership
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 8 hours ago
0mins
Source: Newsfilter
- Marketing Partnership Agreement: Quantum BioPharma has signed a six-month marketing contract with FinnCom, Inc., totaling $170,500, aimed at enhancing corporate branding and investor awareness, thereby strengthening market competitiveness.
- Transparent Payment Structure: Under the agreement, Quantum BioPharma will pay $20,500 at contract initiation, followed by monthly payments of $25,000, ensuring liquidity and supporting ongoing marketing initiatives.
- Innovative Drug Development: Through its wholly-owned subsidiary Lucid Psycheceuticals, Quantum BioPharma focuses on developing Lucid-MS, a new chemical entity shown to prevent and reverse myelin degradation in preclinical models, marking a significant advancement in multiple sclerosis treatment.
- Equity and Royalties: Quantum BioPharma retains a 19.84% stake in Unbuzzd Wellness Inc. and will receive a 7% royalty on sales, expected to drop to 3% after reaching $250 million, providing a long-term revenue stream for the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QNTM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QNTM
About QNTM
Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The Company has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Quantum BioPharma Announces New Marketing Partnership
- Marketing Partnership Agreement: Quantum BioPharma has signed a six-month marketing contract with FinnCom, Inc., totaling $170,500, aimed at enhancing corporate branding and investor awareness, thereby strengthening market competitiveness.
- Transparent Payment Structure: Under the agreement, Quantum BioPharma will pay $20,500 at contract initiation, followed by monthly payments of $25,000, ensuring liquidity and supporting ongoing marketing initiatives.
- Innovative Drug Development: Through its wholly-owned subsidiary Lucid Psycheceuticals, Quantum BioPharma focuses on developing Lucid-MS, a new chemical entity shown to prevent and reverse myelin degradation in preclinical models, marking a significant advancement in multiple sclerosis treatment.
- Equity and Royalties: Quantum BioPharma retains a 19.84% stake in Unbuzzd Wellness Inc. and will receive a 7% royalty on sales, expected to drop to 3% after reaching $250 million, providing a long-term revenue stream for the company.
See More
Quantum BioPharma Unveils Novel Drug for Multiple Sclerosis
- Significant Market Potential: The global market for multiple sclerosis therapeutics is projected to grow from approximately $27.4 billion in 2024 to $38.62 billion by 2030, highlighting the urgent need for effective therapies, which Quantum BioPharma aims to address with its innovative drug.
- Innovative Drug Development: Quantum BioPharma is developing Lucid-MS, a first-in-class patented drug that targets the myelin sheath directly, with the goal of preventing and potentially reversing its degradation, offering a more effective treatment option beyond current management strategies.
- Patent Protection and Market Strategy: Lucid-MS, as a new chemical entity, has shown potential in preclinical models to prevent myelin degradation, and Quantum retains 100% rights to develop this drug, ensuring a competitive edge in the pharmaceutical market.
- Revenue Sharing Agreement: Quantum BioPharma has established a revenue-sharing agreement with its subsidiary Unbuzzd Wellness Inc., allowing Quantum to receive 7% of sales from Unbuzzd products until total payments reach $250 million, after which the royalty rate drops to 3%, providing a continuous income stream for the company.
See More
Quantum BioPharma Advances New MS Treatment Drug
- New Drug Development: Quantum BioPharma Ltd. is developing Lucid-MS, a first-in-class drug candidate targeting multiple sclerosis by directly addressing the myelin sheath destruction, with plans to enter phase 2 clinical trials, potentially offering new hope to over 2.9 million patients worldwide.
- Urgent Market Demand: With more than 2.9 million people globally suffering from multiple sclerosis and existing treatments unable to halt disease progression, Quantum's innovative drug could fill this market gap and meet the urgent need for effective therapies among patients.
- Strategic Partnerships and Investments: Quantum BioPharma focuses on the research and development of Lucid-MS through its wholly owned subsidiary, Lucid Psycheceuticals Inc., while retaining a 19.84% stake in Unbuzzd Wellness Inc., demonstrating a diversified investment strategy in the biopharmaceutical sector.
- Future Revenue Potential: The agreement with Unbuzzd includes a 7% royalty on sales until total payments reach $250 million, after which the royalty drops to 3%, providing a continuous revenue stream that supports future research and development funding.
See More
Quantum BioPharma Advances Novel MS Drug Candidate Lucid-MS
- Drug Development Progress: Quantum BioPharma is advancing Lucid-MS, a novel drug candidate targeting multiple sclerosis by directly protecting the myelin sheath, with plans to enter phase 2 clinical trials that could transform current treatment paradigms.
- Significant Market Demand: The global market for MS therapeutics is projected to reach $27.4 billion in 2024 and grow to $38.62 billion by 2030, highlighting the urgent need for effective treatments, with Quantum BioPharma's innovative drug poised to address this gap.
- Successful Clinical Trials: The phase 1 clinical trial for Lucid-MS has been successfully completed, demonstrating a favorable safety profile and good tolerability, laying the groundwork for subsequent patient trials that could offer unprecedented potential for restoring lost functions.
- Collaborative Research Prospects: Quantum BioPharma is collaborating with Massachusetts General Hospital to utilize advanced imaging techniques to assess Lucid-MS's effectiveness, which could provide direct evidence of the drug's clinical impact and further accelerate its path to market.
See More
Quantum BioPharma Advances Novel MS Drug Candidate Lucid-MS into Phase 2 Trials
- Drug Development Progress: Quantum BioPharma's Lucid-MS is advancing into Phase 2 clinical trials, aiming to directly target the myelin sheath in multiple sclerosis (MS) patients, potentially filling a significant gap in current treatments and improving patient quality of life.
- Significant Market Potential: The global market for MS therapeutics was valued at approximately $27.4 billion in 2024 and is projected to reach $38.62 billion by 2030, highlighting the urgent need for effective therapies, with Quantum BioPharma's innovative drug poised to capture a substantial share.
- Successful Clinical Trials: Lucid-MS demonstrated a favorable safety and tolerability profile in Phase 1 trials, successfully completing dosing among healthy volunteers, laying the groundwork for subsequent patient trials, and offering new hope for MS patients if results are positive.
- Strong Scientific Team: Quantum BioPharma boasts a top-tier scientific team, including experts with extensive experience in medicinal chemistry and neurology, ensuring a rigorous development process for Lucid-MS, which aims to be the first treatment to directly protect the myelin sheath.
See More
Quantum BioPharma Advances Novel MS Drug Candidate
- Drug Development Breakthrough: Quantum BioPharma Ltd. is advancing its first-in-class drug candidate, Lucid-MS, which targets the myelin degradation mechanism in multiple sclerosis, preparing to enter phase 2 clinical trials and potentially offering new treatment options for over 2.9 million patients.
- Significant Market Need: With more than 2.9 million people affected by multiple sclerosis globally, existing therapies fail to halt disease progression, and the development of Lucid-MS aims to fill this gap, addressing the urgent need for effective treatments among patients.
- Strategic Partnership and Revenue: Quantum retains a 19.84% stake in Unbuzzd Wellness Inc. and has established a 7% royalty agreement on sales, which will drop to 3% after reaching $250 million in sales, providing a continuous revenue stream for the company.
- Innovative Drug Potential: As the first drug candidate targeting myelin, if Lucid-MS successfully reaches the market, it could not only transform the treatment landscape for multiple sclerosis but also propel Quantum BioPharma's further development in the neurodegenerative disease sector.
See More
Quantum BioPharma Announces New Marketing Partnership
- Marketing Partnership Agreement: Quantum BioPharma has signed a six-month marketing contract with FinnCom, Inc., totaling $170,500, aimed at enhancing corporate branding and investor awareness, thereby strengthening market competitiveness.
- Transparent Payment Structure: Under the agreement, Quantum BioPharma will pay $20,500 at contract initiation, followed by monthly payments of $25,000, ensuring liquidity and supporting ongoing marketing initiatives.
- Innovative Drug Development: Through its wholly-owned subsidiary Lucid Psycheceuticals, Quantum BioPharma focuses on developing Lucid-MS, a new chemical entity shown to prevent and reverse myelin degradation in preclinical models, marking a significant advancement in multiple sclerosis treatment.
- Equity and Royalties: Quantum BioPharma retains a 19.84% stake in Unbuzzd Wellness Inc. and will receive a 7% royalty on sales, expected to drop to 3% after reaching $250 million, providing a long-term revenue stream for the company.
See More
Quantum BioPharma Unveils Novel Drug for Multiple Sclerosis
- Significant Market Potential: The global market for multiple sclerosis therapeutics is projected to grow from approximately $27.4 billion in 2024 to $38.62 billion by 2030, highlighting the urgent need for effective therapies, which Quantum BioPharma aims to address with its innovative drug.
- Innovative Drug Development: Quantum BioPharma is developing Lucid-MS, a first-in-class patented drug that targets the myelin sheath directly, with the goal of preventing and potentially reversing its degradation, offering a more effective treatment option beyond current management strategies.
- Patent Protection and Market Strategy: Lucid-MS, as a new chemical entity, has shown potential in preclinical models to prevent myelin degradation, and Quantum retains 100% rights to develop this drug, ensuring a competitive edge in the pharmaceutical market.
- Revenue Sharing Agreement: Quantum BioPharma has established a revenue-sharing agreement with its subsidiary Unbuzzd Wellness Inc., allowing Quantum to receive 7% of sales from Unbuzzd products until total payments reach $250 million, after which the royalty rate drops to 3%, providing a continuous income stream for the company.
See More
Quantum BioPharma Advances New MS Treatment Drug
- New Drug Development: Quantum BioPharma Ltd. is developing Lucid-MS, a first-in-class drug candidate targeting multiple sclerosis by directly addressing the myelin sheath destruction, with plans to enter phase 2 clinical trials, potentially offering new hope to over 2.9 million patients worldwide.
- Urgent Market Demand: With more than 2.9 million people globally suffering from multiple sclerosis and existing treatments unable to halt disease progression, Quantum's innovative drug could fill this market gap and meet the urgent need for effective therapies among patients.
- Strategic Partnerships and Investments: Quantum BioPharma focuses on the research and development of Lucid-MS through its wholly owned subsidiary, Lucid Psycheceuticals Inc., while retaining a 19.84% stake in Unbuzzd Wellness Inc., demonstrating a diversified investment strategy in the biopharmaceutical sector.
- Future Revenue Potential: The agreement with Unbuzzd includes a 7% royalty on sales until total payments reach $250 million, after which the royalty drops to 3%, providing a continuous revenue stream that supports future research and development funding.
See More
Quantum BioPharma Advances Novel MS Drug Candidate Lucid-MS
- Drug Development Progress: Quantum BioPharma is advancing Lucid-MS, a novel drug candidate targeting multiple sclerosis by directly protecting the myelin sheath, with plans to enter phase 2 clinical trials that could transform current treatment paradigms.
- Significant Market Demand: The global market for MS therapeutics is projected to reach $27.4 billion in 2024 and grow to $38.62 billion by 2030, highlighting the urgent need for effective treatments, with Quantum BioPharma's innovative drug poised to address this gap.
- Successful Clinical Trials: The phase 1 clinical trial for Lucid-MS has been successfully completed, demonstrating a favorable safety profile and good tolerability, laying the groundwork for subsequent patient trials that could offer unprecedented potential for restoring lost functions.
- Collaborative Research Prospects: Quantum BioPharma is collaborating with Massachusetts General Hospital to utilize advanced imaging techniques to assess Lucid-MS's effectiveness, which could provide direct evidence of the drug's clinical impact and further accelerate its path to market.
See More
Quantum BioPharma Advances Novel MS Drug Candidate Lucid-MS into Phase 2 Trials
- Drug Development Progress: Quantum BioPharma's Lucid-MS is advancing into Phase 2 clinical trials, aiming to directly target the myelin sheath in multiple sclerosis (MS) patients, potentially filling a significant gap in current treatments and improving patient quality of life.
- Significant Market Potential: The global market for MS therapeutics was valued at approximately $27.4 billion in 2024 and is projected to reach $38.62 billion by 2030, highlighting the urgent need for effective therapies, with Quantum BioPharma's innovative drug poised to capture a substantial share.
- Successful Clinical Trials: Lucid-MS demonstrated a favorable safety and tolerability profile in Phase 1 trials, successfully completing dosing among healthy volunteers, laying the groundwork for subsequent patient trials, and offering new hope for MS patients if results are positive.
- Strong Scientific Team: Quantum BioPharma boasts a top-tier scientific team, including experts with extensive experience in medicinal chemistry and neurology, ensuring a rigorous development process for Lucid-MS, which aims to be the first treatment to directly protect the myelin sheath.
See More
Quantum BioPharma Advances Novel MS Drug Candidate
- Drug Development Breakthrough: Quantum BioPharma Ltd. is advancing its first-in-class drug candidate, Lucid-MS, which targets the myelin degradation mechanism in multiple sclerosis, preparing to enter phase 2 clinical trials and potentially offering new treatment options for over 2.9 million patients.
- Significant Market Need: With more than 2.9 million people affected by multiple sclerosis globally, existing therapies fail to halt disease progression, and the development of Lucid-MS aims to fill this gap, addressing the urgent need for effective treatments among patients.
- Strategic Partnership and Revenue: Quantum retains a 19.84% stake in Unbuzzd Wellness Inc. and has established a 7% royalty agreement on sales, which will drop to 3% after reaching $250 million in sales, providing a continuous revenue stream for the company.
- Innovative Drug Potential: As the first drug candidate targeting myelin, if Lucid-MS successfully reaches the market, it could not only transform the treatment landscape for multiple sclerosis but also propel Quantum BioPharma's further development in the neurodegenerative disease sector.
See More
